Liver Transplant for Larger Hepatocellular Carcinoma in Malatya: The Role of GGT and AFP

I

Inonu University

Status

Completed

Conditions

Liver Transplant Disorder
Hepatocellular Carcinoma

Treatments

Procedure: Liver transplantation

Study type

Observational

Funder types

Other

Identifiers

NCT04412161
GGT-HCC-6CM

Details and patient eligibility

About

Retrospective data on 50 prospectively-collected HCC patients with beyond-Milan criteria with >6cm tumors were analyzed. 5-year OS of 76.2% was found in patients with both AFP <200 ng/ml and GGT <104 IU/mL with tumors less than 10 cm diameter. Thus, GGT values add to AFP in patient prognosis.

Full description

Background:A retrospective analysis was performed of prospectively-collected transplant data on outcomes of patients with large size HCCs,to examine possible prognostically-useful factors.Methods:A total of 50 patients having tumors greater than 6cm maximum diameter were identified. Their survival and full clinical characteristics were examined, with respect to serum AFP and GGT levels.Results:Using ROC analysis, cutoff values of AFP 200 ng/ml and GGT 104 IU/ml were identified and used in this study. Significantly longer overall-survival and disease-free-survival were found for patients who had lower values of either parameter, compared with higher values.Even greater differences in survival were found when the 2 parameters were combined, with best survival (5-year OS of 76,2% versus 0%, p=0.002).The most consistent clinical correlates for these longer survivals were degree of tumor differentiation and absence of microscopic portal venous invasion.Two tumor size bands were identified,to search for the limits of this approach with larger tumors, namely 6-10 and >10cm.Combination parameters in 6-10cm band reflected 5-year OS of 76,2% vs. 0%,in patients with low AFP plus low GGT vs. other groups.Beyond 10cm,no patients had low AFP plus low GGT.Conclusions:AFP and GGT,both singly and together, represent a simple prognostic identifier for patients with large size HCCs being treated by liver transplantation.

Enrollment

50 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Liver transplant patients with maximum tumor diameter greater than 6 cm of hepatocellular carcinoma

Exclusion criteria

  • Early postoperative mortality (within 90 days)
  • Advanced stage tumors (explant patology revealed that tumor continues in the surgical cite such as positive lymph node metastases, macroscopic portal vein trombosis, diaphragmatic invasion, etc)

Trial design

50 participants in 1 patient group

Extra-Malatya
Description:
Liver transplant patients with MTD>6 cm of HCC
Treatment:
Procedure: Liver transplantation

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems